Filtered By:
Drug: Diovan

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 78 results found since Jan 2013.

Subcutaneous implanted cardioverter ‐defibrillator in ventricular noncompaction, coronary artery disease and stroke
This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - July 13, 2021 Category: Cardiology Authors: Claudia St öllberger, Edmund Gatterer, Matthias Hasun, Zsuzsanna Arnold, Josef Finsterer Tags: CASE REPORT Source Type: research

Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk.
CONCLUSION: In the high-risk hypertensive patients of the VALUE trial achieving more frequently BP <140/90 mmHg, but not <130/80 mmHg, showed principally the same protective effect on overall and cause-specific cardiovascular outcomes in patients with diabetes mellitus and in the general high-risk hypertensive population. PMID: 33403890 [PubMed - as supplied by publisher]
Source: Blood Pressure - January 8, 2021 Category: Hematology Tags: Blood Press Source Type: research

Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension.
CONCLUSION: In mostly elderly high-risk hypertensive patients with type 2 diabetes mellitus participating in the VALUE trial, achieving more frequently BP <140/90 mmHg showed a marked protective effect on overall and all cause-specific cardiovascular outcomes. This was not the case for a more frequent achievement of the more intensive BP target, i.e. <130/80 mmHg. PMID: 33403886 [PubMed - as supplied by publisher]
Source: Blood Pressure - January 8, 2021 Category: Hematology Tags: Blood Press Source Type: research

A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy
AbstractPurpose of ReviewTo highlight pharmacological and non-pharmacological approaches to reversing hypertensive left ventricular hypertrophy (LVH). We identify high-risk phenotypes that may benefit from aggressive blood pressure (BP) management to prevent incident outcomes such as the development of atherosclerotic cardiovascular disease, stroke, and heart failure.Recent FindingsLVH is a modifiable risk factor. Intensive BP lowering (systolic BP<  120 mmHg) induces greater regression of electrocardiographic LVH than standard BP targets. The optimal agents for inducing LVH regression include renin–angiotensinogen...
Source: Current Hypertension Reports - September 4, 2020 Category: Primary Care Source Type: research

Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis.
CONCLUSIONS: ACEi/ARB and MRA can be safely used in CA, provided that no contraindications are present, treatment is started at a low dose and slowly up-titrated, and patients are monitored quite closely. Beta-blocker therapy is less tolerated in patients with AL amyloidosis and/or worse haemodynamic function. PMID: 32475765 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - May 27, 2020 Category: Internal Medicine Authors: Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M Tags: Eur J Intern Med Source Type: research

Effects of Blood Pressure Lowering Agents on Cardiovascular Outcomes in Weight Excess Patients: A Systematic Review and Meta-analysis
ConclusionsIn hypertensive subjects with excess weight, diuretics are more effective for preventing HF and stroke than CCB and ACEI, respectively. CCB are a good first-line choice for prevention of cardiovascular disease, except HF.
Source: American Journal of Cardiovascular Drugs - January 2, 2020 Category: Cardiology Source Type: research

Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
LCZ696 (sacubitril/valsartan) is an angiotensin receptor-neprilysin inhibitor and has shown beneficial effects in patients with heart failure. However, whether LCZ696 protects against left atrial (LA) and LA appendage (LAA) dysfunction is still unclear. The present study aimed to assess the efficacy of LCZ696 for improving the function of LA and LAA. We performed both a retrospective study comparing LCZ696 with angiotensin receptor blockers (ARBs) to assess the efficacy of LCZ696 in patients with atrial fibrillation and an animal study in a mouse model with pressure overload. LA peak systolic strain, LAA emptying flow velo...
Source: Frontiers in Pharmacology - October 28, 2019 Category: Drugs & Pharmacology Source Type: research

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research

Antibiotic use linked to increased risk of heart attack and stroke in women
Risk is greatest for older women who take antibiotics for more than two months Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Cardio risk raised in people using long-acting bronchodilators Recurrent stroke more likely at very low BP Rising use of antithrombotics linked to subdural haematoma Adding insulin to metformin linked to higher mortality
Source: OnMedica Latest News - May 27, 2019 Category: UK Health Source Type: news

Treatment of hypertension for low-risk patients questioned
Study funds little evidence of benefits from treatment Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Avoid BP-lowering drugs in stroke Adding insulin to metformin linked to higher mortality Stroke rate higher in HIV patients Recurrent stroke more likely at very low BP
Source: OnMedica Latest News - November 1, 2018 Category: UK Health Source Type: news

Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat
Conclusion: The dual angiotensin II type 1 receptor/neutroendopeptidase inhibition significantly increased atrial natriuretic peptide level and reduced BP. Complete prevention of stroke was achieved in this model. The ability of sacubitril/valsartan to reduce organ damage progression was superior to that of valsartan alone. ARNi may represent a highly effective therapeutic agent to protect from target organ damage development in hypertension.
Source: Journal of Hypertension - September 1, 2018 Category: Cardiology Tags: ORIGINAL PAPERS: Treatment Source Type: research

Sacubitril-Valsartan versus Standard Anti-Hypertensives in Left Ventricular Assist Device Patients
Hypertension is a common comorbidity affecting patients with left ventricular assist devices (LVAD). Left uncontrolled, it may lead to a decrease in LVAD support and increase the risk for stroke. The ISHLT defines hypertension in LVAD patients as a mean arterial pressure (MAP) of> 90 mmHg and recommends aggressive management utilizing standard heart failure medications. Sacubitril-valsartan (Entresto ®) is an angiotension II blocker-neprilysin inhibitor with potent anti-hypertensive effects approved for the treatment of heart failure with a reduced ejection fraction.
Source: Journal of Cardiac Failure - August 1, 2018 Category: Cardiology Authors: Erika Nicolsen, Lisa Curran, Stephanie Dixon, Molly Reece, Sarah Herbert, Amy Clegg, Michael Tillery, Daniel Bensimhon, Dalton McLean Tags: 070 Source Type: research

India launches probe as Chinese company recalls BP drug
Valsartan is used to treat patients with high blood pressure in order to reduce complications such as heart attack and stroke. Both the importer and the manufacturer, Zhejiang Huahai Pharmaceuticals, will be issued notice soon.
Source: The Economic Times Healthcare and Biotech News - July 20, 2018 Category: Pharmaceuticals Source Type: news

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
CONCLUSION: Effective reduction of blood pressure to accepted goals is the key to reduce the risk of CV events and stroke. Dual inhibition of neprilysin and the angiotensin receptor with sacubitril/valsartan may represent an attractive and serendipitous therapeutic approach for a range of CV diseases, including hypertension and HF, in which vasoconstriction, volume overload and neuro-hormonal activation play a part in pathophysiology. Sacubitril/Valsartan appears to be more efficacious in reducing blood pressure than currently available ACEi and ARBs with a similar safety and tolerability profile. Besides, pleiotropic bene...
Source: Indian Heart J - July 1, 2018 Category: Cardiology Authors: Dargad RR, Prajapati MR, Dargad RR, Parekh JD Tags: Indian Heart J Source Type: research

Sacubitril/Valsartan: A Novel Angiotensin Receptor-Neprilysin Inhibitor
Conclusion Effective reduction of blood pressure to accepted goals is the key to reduce the risk of CV events and stroke. Dual inhibition of neprilysin and the angiotensin receptor with sacubitril/valsartan may represent an attractive and serendipitous therapeutic approach for a range of CV diseases, including hypertension and HF, in which vasoconstriction, volume overload and neuro-hormonal activation play a part in pathophysiology. Sacubitril/Valsartan appears to be more efficacious in reducing blood pressure than currently available ACEi and ARBs with a similar safety and tolerability profile. Besides, pleiotropic benef...
Source: Indian Heart Journal - January 9, 2018 Category: Cardiology Source Type: research